Company* |
Product |
Description |
Indication |
Status |
| | ||||
CANCER | ||||
Corixa Corp. |
Bexxar |
A radioimmunotherapy; tositumomab and iodine-131 tositumomab |
Non-Hodgkin's lymphoma |
Health Canada accepted Corixa's new drug submission for Bexxar under a priority review (8/26) |
|
||||
International Wex Technologies Inc. (Canada; VSE:WXI) |
Tectin |
Analgesic; TTX with ability to reduce pain |
Cancer |
Company concluded a Phase IIa trial in cancer patients with severe pain conducted in Canada (8/8) |
|
||||
Peregrine Pharmaceuticals Inc. (PPHM) and MediPharm Biotech Inc.* (China) |
-- |
Iodine-131 radiolabeled tumor necrosis therapy monoclonal antibody |
Advanced lung cancer |
MediPharm received marketing approval in China (8/13) |
|
||||
PharmaMar |
Yondelis |
Trabectedin; ET-743; antitumor drug derived from the marine organism Ecteinascidia turbinata, a "sea squirt," or tunicate |
Soft tissue sarcoma |
Company filed to appeal against the negative opinion from the Committee for Proprietary Medicinal Products issued July 24 that recommends against granting marketing approval in the European Union for Yondelis (8/13) |
|
||||
CARDIOVASCULAR | ||||
Axovan AG* (Switzerland) |
Clazosentan |
Endothelin A |
Vasospasm subsequent to subarachnoid hemorrhage |
Phase II data from a trial conducted in Germany showed the compound is safe and well tolerated (8/12) |
|
||||
INFECTION | ||||
Immtech International Inc. (AMEX:IMM) |
DB289 |
Oral anti-infective; dicationic pharmaceutical compound |
Malaria |
Phase IIa data showed DB289 was safe and efficacious in Thai malaria patients (8/25) |
|
||||
MISCELLANEOUS | ||||
Encysive Pharmaceuticals Inc. (ENCY) |
Bimosiamose |
Small-molecule selectin antagonist |
Asthma |
Clinical results showed it could decrease late asthmatic response in patients following allergen challenge; the trial was con- ducted in Germany (8/5) |
|
||||
Lilly ICOS LLC (joint venture of Eli Lilly and Co. and ICOS Corp.; ICOS) |
Cialis |
An oral PDE5 inhibitor |
Erectile dysfunction |
Cialis was approved in Mexico (8/28) |
|
||||
Paladin Labs Inc. (Canada; TSE:PLB) |
Fidelin |
Dehydroepiandrosterone/ DHEA |
Adrenal insufficiency |
European regulatory authorities granted orphan designation to Fidelin (8/6) |
|
||||
| | ||||
Notes: | ||||
* Privately held | ||||
Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
AMEX = American Stock Exchange; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. | ||||
To read more on related topics, click on one of the words below.